A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Inclusion Criteria:

1. Histologically confirmed CD20-positive B-cell non-Hodgkin lymphoma;
2. Relapse or refractory after receiving at least 2 standard treatmentregimens;（Definition of refractory: Patients who did not reach PR in two cycles or CRin four cycles）
3. At least one measurable tumor lesion with the longest transverse diameter ≥ 1.5cm;
4. Previously received anti-tumor treatment (such as radiotherapy, chemotherapy, hormonetherapy, biotherapy, immunotherapy) at least 28 days before the first administrationof this study;
5. The toxicity of previous anti-tumor treatment has been restored to ≤ grade 1 asdefined by NCI-CTCAE v5.0 (except for alopecia)；
6. The laboratory inspection results must meet the following requirements:（It is notallowed to give any blood components, short acting cell growth factor, albumin andother drugs within 7 days before laboratory examination; Long acting cell growthfactor is not allowed to be given within the first 14 days）：

• Hematology: white blood cell count (WBC) ≥ 3 × 109 / L, absolute neutrophil count (ANC) ≥ 1.5 × 109 / L, platelet (PLT) ≥ 100 × 109 / L, hemoglobin (HGB) > 90g /L;
• Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal value, and total bilirubin (TBIL) ≤ 1.5times the upper limit of normal value;
• Renal function：Serum creatinine (Cr) ≤ 2 times the upper limit of normal value;
• Coagulation function：International normalized ratio (INR) ≤ 1.5 upper limit ofnormal value and activated partial thromboplastin time (APTT) ≤ 1.5 upper limitof normal value (The patients were not treated with anticoagulation beforeenrollment);
• Measured value / predicted value of vital capacity (VC) ≥ 60%, or predicted valueof carbon monoxide diffusion function (DLCO) ≥ 50%;

7. ≥ 18 years , gender is not limited;
8. ECOG performance status 0-1;
9. Life expectancy of greater than 3 months;
10. Female and male patients of childbearing age and their spouses are willing to carryout adequate contraception throughout the study period, and female patients ofchildbearing age must have negative serum pregnancy test within 7 days before thefirst administration;
11. Patients voluntarily agree to participate in the study and to sign the informedconsent form.

Exclusion Criteria: Patients who meet any of the following criteria will be excluded:

1. Received rituximab within 3 months before the first medication;
2. Rituximab ADA positive in peripheral blood at the time of screening;
3. The residual concentration of rituximab in peripheral blood > 24ug / ml at screening;
4. A clear history of drug allergy, and a history of ingredient allergy to heterogeneousproteins, biological agents or test drugs;
5. Active hepatitis B or C (HBsAg positive and / or HBcAb positive and HBV DNA ≥ 104 copynumber or ≥ 4000IU/ml; HCV antibody positive) or human immunodeficiency virus (HIV)antibody positive;
6. Tumor-infiltrating diseases of the central nervous system;
7. Accompanied by peripheral or central nervous system diseases;
8. Investigator-assessed diabetes uncontrolled by drug therapy;
9. Patients with other malignancies within the past 5 years;
10. With active autoimmune diseases (such as systemic lupus erythematosus, rheumatoidarthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, etc.);
11. Accompanied by the following serious cardiovascular diseases:
12. Myocardial infarction in nearly 6 months of screening period;
13. Unstable angina pectoris in the screening period of nearly 3 months;
14. Cardiac insufficiency (cardiac function grade ≥ NYHA class II);
15. Severe arrhythmia (e.g., persistent ventricular tachycardia, ventricularfibrillation);
16. Prolonged QTc interval (male > 450 ms, female > 470 ms);
17. Second or third degree heart block;
18. Drug-poorly controlled hypertension (systolic blood pressure > 160mmHg ordiastolic blood pressure > 100mmHg);
19. Accompanied by other serious diseases and serious active infections (such aspneumonia, active tuberculosis, interstitial lung disease, etc.);
20. Received hematopoietic growth factor treatment within 1 week prior to firstadministration, including colony stimulating factor, interleukin or blood transfusion;
21. The dosage of steroid hormone (prednisone phase equivalent) used greater than 20mg/day within 1 month prior to first administration for more than 14 consecutive days orimmunosuppressive treatment;
22. Various vaccines were inoculated within 1 month prior to first administration;
23. Major surgery (except diagnostic biopsy) within 1 month prior to first administration;
24. Patients who received autologous stem cell transplantation within 3 months prior tofirst administration;
25. Patients who have received allogeneic stem cell transplantation in the past;
26. Patients with infusion reaction above grade III after previous monoclonal antibodytreatment;
27. Participate in clinical trials of other drugs or medical devices within 1 month priorto first administration;
28. Patients previously treated with CAR-T;
29. Investigators assessed as unsuitable to participate in this study for other reasons。